# Surefire Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surefire-medical

- Industry: Medical Devices & Equipment
- Headquarters: Westminster, US
- Website: www.surefiremedical.com
- Total disclosed funding: $62M
- Latest round: Series D (Mar 2, 2017)
- Investors on record: 6

## About

Surefire Medical, Inc. is a medical technology company specializing in innovative solutions for oncology, particularly focusing on enhancing drug delivery systems for cancer treatment.Founded in 2009 and headquartered in Westminster, US, Surefire Medical, Inc. specializes in advanced drug delivery systems. The company has undergone strategic developments, particularly in its product offerings. Brenda Zimmerman-Vertin and Mary Szela serve as CEOs. In March 2017, Surefire Medical raised USD 12.8 mn in Series D funding led by ORI Capital, marking a significant milestone in its funding history. The total amount raised by the company now stands at USD 12.8 mn.Surefire Medical, Inc. offers innovative therapeutic solutions aimed at improving cancer treatment efficacy. The company's flagship product is the proprietary Pressure-Enabled Drug Delivery™ (PEDD™) system, which enhances drug penetration by modulating pressure and flow. This technology has been utilized in over 18,000 procedures, illustrating its application in tackling challenging malignancies.Surefire Medical generates revenue through direct sales of its medical devices, including the PEDD™ system, to hospitals and oncology clinics. The revenue model emphasizes direct transactions with healthcare providers, reflecting the specialized nature of its offerings tailored for cancer treatment.Surefire Medical plans to leverage its recent funding of USD 12.8 mn from the Series D round, completed in March 2017, to enhance its product development and expand into new markets. The company is focused on launching new products designed for improving cancer treatment outcomes while exploring opportunities to enter additional geographic regions, particularly in North America and Europe, over the next few years.

## Funding rounds

- Series D, Mar 2, 2017, $13M — ORI Capital
- Series C, Dec 2, 2015, $15M — Tullis Health Investors, MCG Capital, High Country Venture, Partisan Management Group, KMG Capital Partners
- Series C, Jun 12, 2015, $11M — Tullis Health Investors, Partisan Management Group
- Series B, Sep 16, 2013, $16M — MCG Capital, High Country Venture, Partisan Management Group
- Series A, Jul 6, 2011, $2.8M — High Country Venture, Partisan Management Group
- Series A, Apr 26, 2011, $3.7M — High Country Venture, Partisan Management Group

## Investors

- High Country Venture (https://capitalatlas.ai/funds/high-country-venture) — Series A, Series B, Series C
- Partisan Management Group (https://capitalatlas.ai/funds/partisan-management-group) — Series A, Series B, Series C
- MCG Capital (https://capitalatlas.ai/funds/mcg-capital) — Series B, Series C
- Tullis Health Investors (https://capitalatlas.ai/funds/tullis-health-investors) — Series C
- KMG Capital Partners — Series C
- ORI Capital (https://capitalatlas.ai/funds/ori-capital) — Series D